AxoGen

AxoGen CapEx/OCF

The CapEx to Operating Cash Flow Ratio of AxoGen (AXGN) as of Oct 22, 2026 is 461.21 %. In the previous year, CapEx to Operating Cash Flow Ratio was 99.76 % — a change of 362.33% (higher).

CapEx/OCF

461.21 %

YoY

362.33%

Last updated:

CapEx to Operating Cash Flow Ratio of AxoGen is 2025 461.21 % . CapEx to Operating Cash Flow Ratio of AxoGen was 2024 99.76 % . It decreases by 362.33% higher compared to the previous year.

The AxoGen CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-36.97 USD
Jan 1, 2019
-26.30 USD
Jan 1, 2020
-234.75 USD
Jan 1, 2021
-211.86 USD
Jan 1, 2022
-132.29 USD
Jan 1, 2023
-260.99 USD
Jan 1, 2024
99.76 USD
Jan 1, 2025
461.21 USD
The AxoGen CapEx/OCF history
YEARCapEx/OCFYoY
461.21 %+362.33%
99.76 %-138.22%
-260.99 %+97.29%
-132.29 %-37.56%
-211.86 %-9.75%
-234.75 %+792.64%
-26.30 %-28.86%
-36.97 %+164.26%
-13.99 %+31.76%
-10.62 %+149.44%
-4.26 %-25.12%
-5.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AxoGen stock

CapEx to Operating Cash Flow Ratio of AxoGen is 461.21 % in 2025.

CapEx to Operating Cash Flow Ratio of AxoGen changed from 99.76 % to 461.21 %, representing a 362.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio AxoGen since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's AxoGen with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — AxoGen

All Key Metrics — AxoGen